ABP
Abpro Corporation
NASDAQ · Healthcare · Biotechnology · US
$0.52
+0.00%Price chart
Mar 5Mar 10Mar 13Mar 18Mar 23Mar 26Mar 31Apr 6
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$1.36M
MomentumView details →
1D Return
+0.00%
YTD Return
−96.26%
RSI (14)
32.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
Market Cap
$1.36M
RSI (14)
32.0
MomentumView details →
1D Return
+0.00%
YTD Return
−96.26%
SummaryUpdated Sep 1, 2025
Abpro Holdings, Inc. (NASDAQ:ABP) is a biotechnology company founded in 2004 and headquartered in Woburn, Massachusetts. The company went public in March 2022 and was formerly known as Abpro Corporation before changing its name in November 2024. Abpro specializes in developing antibody therapeutics targeting immuno-oncology, ophthalmology, and autoimmune diseases through its proprietary <b>DiversImmune</b> platform technology.
Similar companies
Latest newsMore news →
Miles Suk resigned as Chief Executive Officer of Abpro Holdings, Inc., effective August 19, 2026, and M. Fatih Karatas was appointed Interim Chief Executive Officer, effective August 25, 2026.11d agoAbpro Holdings, Inc. was delisted from NASDAQ on May 28, 2026, for failing to comply with Rule 5550(b)(1) regarding minimum equity.93d ago